Medarex Studying Ipilimumab As First-Line Treatment For Metastatic Melanoma
This article was originally published in The Pink Sheet Daily
Executive Summary
The registrational trial will compare patients treated with ipilimumab and decarbazine with decarbazine alone.
You may also be interested in...
Medarex/Bristol Plan To File Ipilimumab For Metastatic Melanoma Despite Phase II Failure
Totality of the data, clear dose response and limited treatment options in this patient population justify regulatory approval, firms maintain.
Medarex/Bristol Plan To File Ipilimumab For Metastatic Melanoma Despite Phase II Failure
Totality of the data, clear dose response and limited treatment options in this patient population justify regulatory approval, firms maintain.
Pfizer Oncology Head Charles Baum: An Interview With “The Pink Sheet” DAILY (Part 1 Of 2)
Pfizer VP and Oncology Therapeutic Head Charles Baum talks to “The Pink Sheet” DAILY in an exclusive interview about the pharma giant’s increasing research emphasis in cancer drugs, and about pipeline developments, including axitinib in pancreatic cancer and a CTLA4 inhibitor, tremelimumab, for melanoma.